Amneal制药 AMRX 深 沪
等待开盘 06-26 09:30:00 美东时间
17.335
+0.065
+0.38%
华盛通- 最 高17.775
- 今 开17.39
- 成交量 183.14万股
- 最 低 15.93
- 昨 收 17.27
- 总市值 261.76万
- 52周最高 17.775
- 市盈率 静 247.64
- 换手率 1212.87%
- 52周最低 7.665
- 委 比 36.79%
- 总股本 0.00亿
- 历史最高 24.48
- 量 比 1.09
- 振 幅 10.68%
- 历史最低 1.21
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied
06-04 20:05
FDA Takes Step Forward on Testosterone Therapy for Men
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
04-16 23:37
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million
Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up to $1.03 in 2026 earnings.
02-27 22:17
Earnings Outlook For Amneal Pharmaceuticals
Amneal Pharmaceuticals (NASDAQ:AMRX) will release its quarterly earnings report...
02-26 22:01
Amneal Pharmaceuticals Gets FDA's Approval For Biologics Licensing Applications For Boncresa, Oziltus
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug
2025-12-23 05:02
Amneal Pharmaceuticals Announces FDA's Approval For Albuterol Sulfate Inhalation Aerosol
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's albuterol sulfate inhalation aerosol (90 mcg per
2025-12-02 21:09
Amneal Pharmaceuticals Announces U.S. FDA Approves Its Iohexol Injection
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic
2025-11-14 05:03
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Amneal Pharmaceuticals获FDA批准其1%泼尼松龙乙酸酯眼用悬液，计划于2025年第三季度上市。该药物用于治疗 steroid-responsive ocular inflammation， IQVIA数据显示2025年销售额约为2.01亿美元。
2025-06-12 12:00
Amneal to Participate at Upcoming Investor Conferences in June
Amneal Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 5 and Goldman Sachs Global Healthcare Conference on June 10, with executives presenting and a live webcast available.
2025-05-29 20:05
Amneal Pharmaceuticals盘中异动 急速拉升5.02%报8.69美元
北京时间2024年12月03日03时02分，Amneal Pharmaceuticals, Inc.（AMRX.us）股票出现异动，股价大幅上涨5.02%。截至发稿，该股报8.69美元/股，成交量126.784万股，换手率0.41%，振幅5.80%。 最近的财报数据显示，该股实现营业收入7.02亿美元，净利润-156000.00美元，每股收益0.00美元，毛利2.70亿美元，市盈率-10.09倍。 机构评级方面，在所有4家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。 Amneal Pharmaceuticals, Inc.股票所在的制药行业中，整体...
2024-12-03 03:02
